Reversal of the Activation State of Pro-fibrotic CD206 Positive Macrophages by Therapeutic Peptide AUR300 in Systemic Sclerosis (ACR Convergence 2023) - Sep 24, 2023 - Abstract #2359; Pres time: Nov 14, 2023; 09:00 AM - 11:00 AM; Location: Poster Hall; in person; " Suction blister fluid-derived cells from lesional skin were profiled by 10X RNAseq matched to AKOYA antibody staining to characterise the tissue resident immune cells, including the CD206 positive macrophages of interest (n=12 SSc patients and controls).Tissue culture modelling with patients' blood monocyte-derived macrophages and disease fibroblasts (n=6 SSc cell lines), as well as bleomycin induced lung fibrosis as a model of organ involvement, were used to determine efficacy and mechanism of action of the therapeutic AUR300 peptide.Soluble CD206 (sCD206) (n=140 SSc and n=80 healthy control (HC) plasma samples) and cellular CD206 (n=17 SSc, n=9 HC macrophage lines) were investigated as potential biomarkers of SSc disease activity. In disease tissue, CD206 positive macrophages represent a spectrum of activation states, from pro-resolving MERTK IL-10 expressing cells, to pathogenic cells releasing profibrotic cytokines and growth factors in activating..."
Fibrosis • Immunology • Inflammation • Respiratory Diseases • Scleroderma • Systemic Sclerosis • CD63 • CD68 • IL10 • IL6 • LAMP3 • MERTK • MRC1 • SIGLEC1
|
|
Sandra Lopez1; Bahja Ahmed Abdi1; Linda Lei1; Anas Al-Oweidi1; Claire Macfadyen1; Lydia Nagib1; Sarah Ive1; Anshul Kumar1; Teresa Collins1; Jennifer Cross2; Christopher Denton1; David Abraham1; Clayton Yates3; Charles Garvin4; Henry Lopez4; George Martin5; Richard Stratton1
|